Last reviewed · How we verify
Melissa officinalis
At a glance
| Generic name | Melissa officinalis |
|---|---|
| Also known as | homeopathic medicine |
| Sponsor | Universidade Federal do Rio de Janeiro |
| Drug class | Standardized Chemical Allergen [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome (NA)
- Quality of Life in Diarrhea-predominant Irritable Bowel Syndrome Taking GABA (NA)
- Efficacy of the Nurtured Heart Approach to Reduce ADHD Behaviors in Children (NA)
- Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cortisol Modulation (NA)
- The Effects of STW 5-II on Duodenal Mucosa and Symptoms in Functional Dyspepsia (PHASE4)
- Oral Bioavailability of the Phenolic Compounds in a Melissa Supplement (NA)
- Evaluation of the Beneficial Effects of a Product Containing Γ-aminobutyric Acid (GABA) on Climacteric Syndrome Disorders (NA)
- Enhancement of Calmness and Mood Following Acute Lemon Balm Supplementation During Cognitive Demand in Adults (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Melissa officinalis CI brief — competitive landscape report
- Melissa officinalis updates RSS · CI watch RSS
- Universidade Federal do Rio de Janeiro portfolio CI